Lukáš
Masaryk‡
a,
Denisa
Weiser Drozdková‡
bc,
Karolina
Słoczyńska
d,
Ján
Moncol’
e,
David
Milde
f,
Radka
Křikavová
a,
Justyna
Popiół
d,
Elżbieta
Pękala
d,
Katarína
Ondrušková
b,
Ivan
Nemec
*ah,
Kateřina
Smešný Trtková
*bcg and
Pavel
Štarha
*a
aDepartment of Inorganic Chemistry, Faculty of Science, Palacký University Olomouc, 17. listopadu 12, 77146 Olomouc, Czech Republic. E-mail: pavel.starha@upol.cz; Tel: +420 585 634 348
bDepartment of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 3, 77515 Olomouc, Czech Republic. E-mail: katerina.smesny@upol.cz; Tel: +420 585 632 455
cInstitute of Molecular and Clinical Pathology and Medical Genetics, Faculty of Medicine, University of Ostrava, Syllabova 19, 703 00 Ostrava, Vítkovice, Czech Republic
dDepartment of Pharmaceutical Biochemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
eDepartment of Inorganic Chemistry, Faculty of Chemical and Food Technology, Slovak University of Technology in Bratislava, 81237 Bratislava, Slovakia
fDepartment of Analytical Chemistry, Faculty of Science, Palacký University Olomouc, 17. listopadu 12, 77146 Olomouc, Czech Republic
gInstitute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 5, 77515 Olomouc, Czech Republic
hCentral European Institute of Technology, Brno University of Technology, Purkyňova 123, 61200 Brno, Czech Republic. E-mail: ivan.nemec@upol.cz; Tel: +420 541 149 269
First published on 3rd May 2023
Platinum-based agents unwaveringly hold their prominent position in cancer treatment. Current research emphasizes finding novel complexes for hard-to-treat cancers with minimum side effects, capable of overcoming resistance. This work presents easy-to-prepare diiodidoplatinum(II) complexes cis-[PtI2(Ln)2] (1–7) with imidazole derivatives (Ln), which were considerably effective against multiple myeloma cell lines U266B1 and KMS12-PE. The leading compound 6 (at 3 μM concentration) extraordinarily reduced viability of U266B1 and KMS12-PE myeloma cells to 3.0% and 1.1%, respectively, and exceeded the conventional platinum-based anticancer drug cisplatin (93.1% and 88.3%, respectively) that is used clinically for the combination therapy of multiple myeloma. Complex 6 was significantly more effective in inducing apoptosis in KMS12-PE cells without interleukin-6 (IL-6) expression than in U266B1 cells with IL-6 expression. Complex 6 also induced apoptosis in co-culture of KMS12-PE with non-cancerous stromal fibroblasts (HS-5), and displayed markedly lower activity in the HS-5 stromal fibroblast cells than in myeloma cells, pointing out its pharmocologically prospective selectivity towards the cancer cells over the normal ones. No caspase 3/7 activity was detected in apoptotic KMS12-PE cells treated by complex 6 indicating a different mechanism of apoptosis action from cisplatin. This work demonstrates that simple non-classical platinum(II) complexes represent a new perspective for a monotherapy of hard-to-treat multiple myeloma.
Moreover, it has been established that the lower response of myeloma cells to conventional treatment, such as glucocorticoids or cytotoxic chemotherapeutics, is connected with the presence of BMSCs. Beneficially, some of the newly approved anti-myeloma drugs are able to circumvent the protective effects of the BM microenvironment.3 This fact demonstrates that in recent years, much progress has been made in the treatment of symptomatic MM, particularly with the development of proteasome inhibitors (e.g. bortezomib, carfilzomib and ixazomib), immunomodulatory drugs (IMiDs; e.g. thalidomide, lenalidomide and pomalidomide), and monoclonal antibodies (e.g. daratumumab, elotuzumab or isatuximab) with pleiotropic anti-myeloma properties.8 Additionally, treatment regimens (e.g. the proteasome inhibitor-based regimen) nowadays usually comprise targeted drug therapy that combines varied classes of drugs to fight the growth of MM.9
Despite these possibilities, MM still remains incurable, and most patients develop resistance to proteasome inhibitors and IMiDs and almost all patients with MM eventually relapse.10 Intensive chemotherapy modes were originally developed to improve response to treatment and overcome chemotherapeutic resistance in patients with relapsed or refractory MM. However, these intensive salvage regimens, such as DCEP which uses dexamethasone with continuous infusions of cyclophosphamide, etoposide, and cisplatin, are associated with significant toxicity.11
Conventional platinum-based drugs (e.g. cisplatin) are not effective for monotherapy of MM but are advantageous in advanced combination treatment (see above). Their irreplaceable role even in the therapy of hard-to-treat cancers is the reason why these metallotherapeutics still represent prominent antineoplastic agents worldwide,12 despite the fact that their application is limited by adverse side effects (e.g. nephro- and hepatotoxicity) and a lack of efficacy against many types of tumours.13 These limitations still motivate the search for new, more effective and safer (metallo)drugs with different mechanism of action (MoA) based not only on platinum but also other transition metals.14 Recent success of such research has brought imifoplatin, i.e. Pt(II) pyrophosphato complex PT-112,15 which is currently evaluated in clinical trials on oncological patients.16 Imifoplatin proves that variation of carrier/leaving ligands in conventional platinum-based drugs can still be a viable design strategy, as this complex practically represents a derivative of oxaliplatin with oxalate substituted with pyrophosphate.
Analogical strategy, this time replacing chlorides by iodides in cisplatin analogues, has also resulted in complexes with high pharmacological potential. Indeed, in the last decade, various cis-diiodidoplatinum(II) complexes have been shown to exhibit higher cytotoxicity connected with different mechanistic effects as compared with chlorido (including cisplatin) and carboxylato analogues.17 The MoA of Pt(II) diiodido complexes likely involves interactions with biomolecules other than DNA, and the formation of protein/peptide adducts has to be considered as well.17–20 In connection to this, we hypothesized that different MoA of diiodidoplatinum(II) complexes from cisplatin could be advantageous in terms of potency against hard-to-treat tumours, such as MM, where cisplatin shows only limited activity. Thus, in this work, the substituted-imidazole-based diiodidoplatinum(II) complexes (1–7; Fig. 1) were studied for their in vitro antiproliferative activity against human multiple myeloma cell lines.
The majority of design strategies for Pt-based agents involves variation of the original structure of the conventional Pt-based drugs. Multiple combinations of leaving and carrier ligands in Pt complexes have been investigated.14,17 This work reports on seven diiodidoplatinum(II) complexes of the general formula cis-[PtI2(Ln)2] (1–7) with various imidazole derivatives (Ln) used as monodentate N-donor ligands. A family of imidazole derivatives represents both natural and synthetic compounds, including anticancer imidazole-based drugs.21,22 Cytotoxic efficacy was previously described for some Pt(II) chlorido complexes bearing various imidazole derivatives.23–25
It should be pointed out that the goals of overcoming the drawbacks of the classical platinum chemotherapy and finding agents for hard-to-treat cancers can most likely be achieved with compounds acting through diverse MoA. It is known in the literature that diiodido Pt(II) complexes of the general formula cis-[PtI2L2] containing varied N-donor heterocyclic ligands (L) exhibited higher cytotoxicity connected with different mechanistic effects as compared with their chlorido and carboxylato analogues.17 For example, complex cis-[Pt(3Braza)2I2] was more potent in MCF-7 breast carcinoma cell line than its dichlorido and oxalato analogues; 3Braza = 3-bromo-7-azaindole.26–28 Thus, we hypothesized for this work that the known cytotoxicity of dichlorido complexes with various imidazole derivatives23–25 could be improved for the new substituted-imidazole-based diiodidoplatinum(II) complexes, which could be, in contrast to cisplatin, potent against hard-to-treat human tumours (i.e. multiple myeloma in this work) as a consequence of their different MoA. Notably, anticancer Pt(II) diiodido complexes with imidazole-based ligands are scarce in the literature.29–31
The ESI+ mass spectra of 1–7 contained the peaks of the {[PtI2(Ln)2] + X}+ species with adequate m/z values and isotopic distribution; X = H+, Na+, K+ or NH4+ (see ESI, Experimental section†). All hydrogen and carbon atoms were identified in the 1H and 13C NMR spectra (ESI, Fig. S1–S7†). The largest 1H NMR coordination shifts (Δδ = 0.53–0.90 ppm) were observed for the C2–H resonances (Fig. 1B), while the other signals of the imidazole ring showed a somewhat lower change of δ (0.22–0.57 ppm). The cis-configuration was confirmed in solution, as 195Pt NMR spectra of 1–7 showed a single resonance in the region characteristic for cis-diiodidoplatinum(II) complexes (ca. −3150 ppm; ESI, Fig. S1–S7†).18,33,34 Additionally, the representative complexes 6 (97.8% at tR = 16.43 min) and 7 (96.3% at tR = 18.00 min) were analysed by reversed–phase high–performance liquid chromatography (RP–HPLC) coupled to mass spectrometry (electrospray ionization, ESI) (Fig. S8†).
Single crystals of sufficient quality were prepared for 3, 4, 5 and 7. X-ray diffraction analysis revealed that all these compounds contained cis-[PtI2(Ln)2] molecules in their crystal structure (Fig. 2 and ESI, Fig. S9 and Table S1†). The Ln ligands coordinate Pt(II) atoms by the N3 atom. The Pt atoms are tetracoordinate with the coordination polyhedron adopting the shape close to square planar. This can be documented by the trans-N–Pt–I angles adopting values close to 180° (174–179°). Also, the values of the cis-angles 86–93° were as expected for the square-planar geometry. The Pt–I bonds adopt the lengths of 2.58–2.60 Å, which are much longer than those observed for the Pt–N bonds (2.01–2.04 Å). All the metal–ligand bond lengths and angles are summarized in the caption of Fig. 2.
![]() | ||
Fig. 2 An Ortep drawing (50% probability level) of the complex molecules in compounds 3 and 4 (see ESI, Fig. S9† for 5 and 7). Colour code: C (grey), H (white), I (purple), N (blue) and Pt (light grey). Selected bond lengths (in Å): 3, d(Pt1–N1) = 2.037(2), d(Pt1–N3) = 2.023(2), d(Pt1–I1) = 2.5880(1), d(Pt1–I2) = 2.5842(2); 4, d(Pt1–N1) = 2.043(2), d(Pt1–N3) = 2.034(2), d(Pt1–I1) = 2.5946(2), d(Pt1–I2) = 2.5838(2); 5, d(Pt1–N1) = 2.030(2), d(Pt1–N3) = 2.042(2), d(Pt1–I1) = 2.5794(2), d(Pt1–I2) = 2.5962(2), d(Pt2–N5) = 2.041(2), d(Pt2–N7) = 2.041(2), d(Pt2–I3) = 2.6014(2), d(Pt2–I4) = 2.5925(2); 7, d(Pt1–N1) = 2.041(3), d(Pt1–N3) = 2.039(3), d(Pt1–I1) = 2.5823(2), d(Pt1–I2) = 2.5871(2), d(Pt2–N5) = 2.030(3), d(Pt2–N7) = 2.035(3), d(Pt2–I3) = 2.5957(3), d(Pt2–I4) = 2.5976(2). |
Besides rare reports on biological investigations of cis-Pt(II)-diiodido complexes with imidazole-based N-donor ligands, also structural information on this type of compounds is rather scarce. The search for this structural motif in the Cambridge Structural Database (version 5.4.1 November 2019)35 gives back only two deposited crystal structures of cis-Pt(II)-diiodido complexes, both with bidentate bis-imidazole ligands.31,36 In other words, complexes 3, 4, 5 and 7 represent the first crystallographically characterized complexes of the cis-[PtI2L2] type with two monodentate imidazoles.
1H NMR experiments proved that complexes 1–7 did not undergo any chemical changes when dissolved in DMF-d7 for 24 h at room temperature (r.t.), since no new signals appeared in their spectra. In the presence of water (i.e., in 50% DMF-d7/50% PBS in D2O; Fig. 3 and ESI, Fig. S10–S16†), complexes 1–3, 5 and 6 were stable as well, as their 1H NMR spectra did not change within the whole-time interval. In contrast, 1H NMR spectra of 4 and 7 showed new signals at t = 24 h, assignable to free ligands L4 and L7. Specifically, the ratio of the parent complexes and released ligands was ca. 9:
1 after 24 h for both complexes. Although 4 and 7 released their Ln ligands (no 1H NMR signals indicating the presence of Pt-containing species with only one Ln ligand were detected), the extent of their decomposition was acceptable with respect to the intended biological analyses.
In the presence of an excess of intracellular thiol GSH (2 molar equiv.; 50% DMF-d7/50% PBS in D2O, pH 7.4), 1–3 were stable for 24 h (ESI, Fig. S10–S16†). In contrast, new signals appeared in 1H spectra of 4–7 involving phenyl-substituted imidazoles (t = 24 h; Fig. 3). These resonances can be unambiguously assigned to the released ligands L4–L7 (measured for comparative purposes under the same experimental conditions). The extent of the Ln release from phenyl-substituted imidazole-based complexes was more or less the same for 4 and 7 in the presence of GSH as compared with the results obtained for the mixture of 50% DMF-d7/50% PBS in D2O (i.e. without GSH). All the studied complexes were inert towards the covalent attack of GSH, because no signals assignable to the Pt–SG adducts were detected in the 1H NMR spectra.
Complexes 1–7 considerably reduced the MM cell viability at the applied 1–3 μM concentrations (Fig. 4 and ESI, Table S2†). More lipophilic benzyl- and phenyl-substituted complexes 2–7 were more antiproliferative active than 1. Complexes 5–7, which contain variously substituted 1-phenyl-1H-imidazoles (L5–L7) were more anti-myeloma active than 4 with unsubstituted 1-phenyl-1H-imidazole (L4). The best-performing complexes 6 and 7 were significantly more potent against both the used myeloma cells than the reference drug cisplatin (ESI, Fig. S17†), known to be involved in various clinical treatment protocols for MM.11,41 Specifically, the 2 μM and 3 μM concentrations of 6 and 7 caused a decrease in the proportion of viable cells of both cell types below 10% (e.g. to 3.0% and 1.1% in U266B1 and KMS12-PE cells, respectively, for 3 μM 6), which was significantly higher as compared with cisplatin (93.1% and 88.3% cell viability, respectively; at 3 μM concentration). Importantly, 7 significantly reduced the myeloma cell viability significantly even at 1 μM concentration to the level of 11.5% (U266B1) and 2.1% (KMS12-PE), implying its extraordinarily high anti-myeloma activity.
The studied diiodidoplatinum(II) complexes, especially the best-performing compounds 6 and 7, showed a high anti-myeloma effect. Lower myeloma cell viability inhibition was previously reported for the other Pt-based drugs oxaliplatin and carboplatin,45 Pt(II) dichlorido complexes with steroidal esters of L-methionine and L-histidine,46 or complexes derived from different d-block elements.47–51 This unprecedented anti-myeloma activity of the studied Pt diiodido complexes is particularly important for their future research, because it offers a possibility of myeloma monotherapy instead of the conventional combination therapy regimens.
Although 6 was not the most antiproliferative active compound (7 showed slightly higher anti-myeloma potency), we decided to use 6 for additional studies of MoA (apoptosis, cell cycle modification), especially because its stability was higher than determined for 7 under the used aqueous conditions.
Myeloma cells proliferate and survive in the BM through physiological and functional interactions with bone marrow stromal cells and surrounding microenvironment.5–7 BM stroma consists of different types of cells including fibroblast stromal cells.52,53 For this reason, non-cancerous stromal fibroblast cell line (HS-5), representing naturally occurring healthy cells of bone marrow physiologically connected with myeloma cells, was used to determine the in vitro biological effect of the leading compound 6 towards non-cancerous cells and its selectivity. Intriguingly, 6 reduced the HS-5 cell viability to 82.5 ± 4.4, 63.0 ± 10.4 and 51.0 ± 3.2% when applied at 1, 2 and 3 μM concentrations, respectively (Fig. 5A and ESI, Fig. S18†). Thus, only a negligible effect of 6 on the cell viability was observed in HS-5 normal fibroblasts. This is particularly important because this observation is highly suggestive of a selective effect of 6 against myeloma cells over healthy stromal fibroblasts. This difference is not connected with the amount of the complex accumulated by the treated cells, because the cellular accumulation of the used complex 6 by HS-5 cells (795 ± 260 ng Pt/106 cells) was higher as compared with both MM cell lines (232 ± 21 ng Pt/106 cells for U266B1, and 171 ± 66 ng Pt/106 cells for KMS12-PE); analysed by inductively coupled plasma-mass spectrometry (ICP-MS) at 1 μM concentration.
Further for comparative purposes, in vitro antiproliferative activity was also tested in several solid tumour cell lines, specifically, in DU-145 prostate cancer, HepG2 hepatocellular cancer and MCF-7 breast cancer (1 μM concentration, MTT assay). At 1 μM concentration level (i.e. equimolar with the lowest tested concentration in the myeloma cells), complex 6 was even less effective in the used solid tumour cell lines (73–97% cell viability), which was not the case of the reference drug cisplatin (Fig. 5B and ESI, Table S3†). Thus, complex 6 was more antiproliferative active in the myeloma cell lines than in the used solid cancer cell lines at 1 μM concentration.
Altogether, these results implied high selectivity of 6 towards MM cells over normal HS-5 stromal fibroblasts, and its higher antiproliferative activity in hard-to-treat MM cells than determined in the solid tumour cells (i.e. different anticancer activity profile).
Regarding the determination of caspase 3/7 activities, the number of viable U266B1 cells (with IL-6 expression) was significantly decreased after treatment with 2 μM (p < 0.001) and 3 μM (p < 0.0001) concentrations of 6, as compared to untreated cells (Fig. 6 and ESI, Fig. S19, Table S4†). The distribution of early apoptotic (EA), late apoptotic (LA) and necrotic (N) populations of the U266B1 cells indicates a dose-dependent effect of the treatment with 6 on the induction of apoptosis (Fig. 6). Yet, the concentration of 1 μM was recognizably insufficient to trigger apoptosis in U266B1 cells.
Similarly, the number of viable KMS12-PE cells determined by the same method significantly decreased (p < 0.05 and p < 0.001, respectively) after treatment with 2 μM and 3 μM concentrations of 6 (Fig. 6 and ESI, Fig. S20, Table S4†), corresponding to the highest proportion of apoptotic cells in the EA phase (Fig. 6). More KMS12-PE cells detected in the LA and N populations corresponds to the reduced number of viable KMS12-PE cells under these experimental conditions (Fig. 4). In contrast to U266B1 cells, the 1 μM concentration of 6 appears to be effective in inducing KMS12-PE cell apoptosis (Fig. 6). In connection with the antiproliferative activity studies (vide supra), the results of the studies of apoptosis induction unambiguously proved that KMS12-PE cells without IL-6 expression are much more susceptible to the treatment by 6 than U266B1 cells with IL-6 expression, because 6 was significantly more effective in reducing cell viability and inducing apoptosis in KMS12-PE cells. Similar results were obtained by Annexin-V/7-AAD staining (ESI, Fig. S21 and Table S5†).
Notably, no caspase activity was detected in the compound 6-treated myeloma cells, which indicated that the ongoing cell death was independent of caspases. This is consistent with previous findings that in myeloma cells, the administration of drugs containing metal ions causes mitochondrial permeabilization by increasing ROS and Ca2+ levels, leading to the induction of caspase-independent apoptosis.54 This process is accompanied by the transfer of cytochrome c, apoptosis inducing factor (AIF) and endonuclease G (EndoG), from the mitochondria to the cytosol.55 AIF then binds directly to DNA, causing chromatin condensation and DNA fragmentation, which is consistent with our investigation and high sub-G1 cell cycle phase population of compound 6-treated myeloma cells (see below).
Also of importance, the caspase-independent apoptosis induced by compound 6 seems to be different from oxaliplatin45 or non-platinum49,50 complexes, which induced caspase-3-dependent apoptosis in myeloma cells. In total, our results are indicative of a different MoA of 6 in myeloma cells as compared with conventional platinum-based anticancer drugs and other types of anti-myeloma active compounds.
The number of viable cells in the co-culture of U266B1 myeloma cells and HS-5 stromal fibroblasts was significantly lower after treatment with 2 and 3 μM concentrations of 6 (p < 0.001 by both caspases 3/7 activities and Annexin-V staining) by comparison with the negative control (Fig. 6 and ESI, Fig. S22, Table S5†). 1 μM concentration of 6 had only a modest effect on apoptosis of co-cultured U266B1 cells.
The number of viable KMS12-PE myeloma cells co-cultured with HS-5 stromal fibroblasts was significantly reduced after application of 2 μM and 3 μM of 6, compared to unaffected viable cells in solvent (p < 0.01 for caspases 3/7 activities, p < 0.0001 for Annexin-V staining) (Fig. 6 and ESI, Fig. S23, Table S5†). Subsequent distribution of apoptotic co-cultured cells in the EA and LA/N populations was increased after treatment with 2 μM and 3 μM of 6 concentrations compared to 1 μM. Notably, the 1 μM concentration of 6 appears to be more effective in inducing apoptosis in co-cultivated KMS12-PE cells than in co-cultivated U266B1 cells, both with HS-5 fibroblasts (Fig. 6).
In total for apoptosis investigations, similar results were observed in myeloma cells alone and their co-cultures with healthy stromal fibroblasts (Fig. 6 and ESI, Tables S4, S5†). This observation is suggestive for low level of deactivation of 6 in the mimicked BM environment consisting of target myeloma cells co-cultured with non-cancerous stromal fibroblasts.
Regarding more sensitive KMS12-PE myeloma cells, concentration of 2 μM and 3 μM caused massive cell death and it is difficult to distinguish between different phases of the cell cycle (Fig. 7B and ESI, Fig. S25, Table S6†). These concentrations of 6 appear to be toxic to the KMS12-PE cells. 1 μM concentration was also effective in inducing the cell cycle alternation of the KMS12-PE cells connected with the detection of ca. 20% cell population in the sub-G1 cell cycle phase. The observed higher susceptibility of the IL-6 non-expressing KMS12-PE cells to apoptosis and cell cycle modifications, than determined for the IL-6 expressing U266B1 cells, may be explained by the expression of IL-6, which could promote survival and further proliferation in myeloma cells.4,42–44
Specifically, in the co-culture of U266B1 and HS-5 cells, 6 induced significantly higher sub-G1 cell cycle phase population at 2 μM (p = 0.003) and 3 μM (p = 0.006) concentrations than observed for non-treated co-cultured cells (Fig. 7B and ESI, Fig. S26, Table S6†). The 1 μM concentration of 6 was not effective enough to induce apoptosis in the U266B1/HS-5 cell co-culture. In contrast to the results obtained for the co-culture of the U266B1 and HS-5 cells, the 1 μM concentration of 6 causes a significant increase in the number of co-cultivated KMS12-PE cells in the sub-G1 phase (p < 0.01; Fig. 7D and ESI, Fig. S27, Table S6†).
For comparative purposes, the cell cycle modification was also studied in HS-5 cells without myeloma cells (Fig. 7E and ESI, Fig. S28†), and only negligible changes were detected between the untreated cells in comparison with the cells treated by 1–3 μM concentration of 6 (ESI, Fig. S29†). This is particularly important, because it underlined the conclusion that the observed biological effects (i.e. induction of apoptosis, cell cycle alternation) connected with MoA of highly active anti-myeloma compound 6 can be unambiguously assigned to the used myeloma cells.
At first, the representative complexes 6 and 7 (and cisplatin for comparative purposes) were studied by 1H NMR for their possible interaction with the model nucleobase GMP, to investigate the affinity of these complexes towards DNA. For the mixtures of the complexes (6, 7) with GMP, no new 1H NMR C8–H resonance of GMP was observed up to 24 h of standing in the dark at r.t. (ESI, Fig. S30†), implying that the studied complexes do not interact covalently with the used model nucleobase. These results also suggested that DNA is most likely not a target for the studied Pt(II) diiodido complexes. The control experiment with DNA-binding anticancer drug cisplatin mixed with GMP resulted in the new resonance of the cisplatin–GMP adduct at 8.91 ppm (ESI, Fig. S30†).26,60
Additionally to the experiments with the DNA model molecule GMP, the same complexes (6, 7, cisplatin) were incubated with double-stranded DNA in 10 mM NaClO4 (24 h, 37 °C). The results proved that the new diiodidoplatinum(II) complexes 6 and 7 interacted with the used DNA molecule to a markedly lower extent than cisplatin. Specifically, only ca. 2% of the Pt(II) diiodido complexes (2.1% for 6 and 1.7% for 7) bound to DNA, while cisplatin platinated the used DNA almost quantitatively (90.7%) under the used cell-free experimental conditions.
Overall, the results of the performed studies of possible DNA interactions with GMP and salmon sperm DNA excluded DNA as the primary intracellular target for the studied complexes 6 and 7, clearly distinguishing their MoA from cisplatin. We hypothesize that the studied anti-myeloma diiodido complexes target a different molecule(s) than DNA and trigger unique responses different from conventional platinum-based drugs. In the field of Pt iodido complexes, such unusual MoA has been reported for compounds interacting with mitotic kinesin Eg520 or for complexes inducing high levels of ROS and interfering with redox homeostasis of the treated cancer cells.61
In this work, a series of seven platinum(II) complexes of the general formula cis-[PtI2(Ln)2] (1–7) with various imidazole derivatives (L1 = 1-methyl-1H-imidazole for 1, L2 = 1-benzyl-1H-imidazole for 2, L3 = 1-benzyl-2-methyl-1H-imidazole for 3, L4 = 1-phenyl-1H-imidazole for 4, L5 = 1-(4-methoxyphenyl)-1H-imidazole for 5, L6 = 1-(4-fluorophenyl)-1H-imidazole for 6, and L7 = 1-(4-chlorophenyl)-1H-imidazole for 7) was prepared and thoroughly characterized, including a single-crystal X-ray analysis of 3, 4, 5 and 7. Desirable characteristics related to mechanism of action different from cisplatin were confirmed by 1H NMR spectroscopy, particularly, the complexes do not form covalent adducts either with reduced glutathione or with guanosine monophosphate. Additionally, only a negligible level of DNA-platination was confirmed after incubation of the presented complexes with salmon sperm DNA in a cell-free medium, thus supplying further evidence for contrasting mechanistic behaviour with respect to cisplatin.
Antiproliferative activity of the complexes was evaluated in two multiple myeloma cell lines (U266B1 and KMS12-PE; PE = pleural effusion due to plasma cell infiltration). The anti-myeloma activity of 1–7 was significantly higher than for the reference platinum-based anticancer drug cisplatin. For example, the cell viability of U266B1 and KMS12-PE cells was extraordinarily reduced to 3.0% and 1.1%, respectively, for the leading compound 6, while remained only slightly reduced (93.1% and 88.3%, respectively) for the cisplatin-treated myeloma cells (both compounds applied at 3 μM concentration). Interestingly, complex 6 appeared to induce cell apoptosis significantly more efficiently in KMS12-PE cells without interleukin-6 (IL-6) expression than in U266B1 cells with IL-6 expression. Complex 6 also induced apoptosis in the co-cultures of myeloma cells with non-cancerous stromal fibroblasts. The observed cancer cell death was clearly not dependent on caspases, since no caspase 3/7 activity was detected in the apoptotic myeloma cells treated by 6. This investigation represents a new perspective and challenge for metal-based anti-myeloma therapy, including a monotherapy of this hard-to-treat type of cancer.
Footnotes |
† Electronic supplementary information (ESI) available: Experimental section, 1H, 13C and 195Pt NMR spectra, crystal data and structure refinement, stability studies, viability data (multiple myeloma (MM), stromal fibroblasts, solid cancer cells); flow cytometry data (apoptosis studies and cell cycle). CCDC 2211813 (3), 2211814 (4), 2211815 (5) and 2211816 (7). For ESI and crystallographic data in CIF or other electronic format see DOI: https://doi.org/10.1039/d3qi00327b |
‡ These authors contributed equally. |
This journal is © the Partner Organisations 2023 |